Zentalis Pharmaceuticals
ZNTL
134 hedge funds and large institutions have $2.32B invested in Zentalis Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 34 funds opening new positions, 59 increasing their positions, 27 reducing their positions, and 10 closing their positions.
311% more call options, than puts
Call options by funds: $4.45M | Put options by funds: $1.08M
240% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 10
119% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 27
102% more capital invested
Capital invested by funds: $1.15B → $2.32B (+$1.17B)
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
22% more funds holding
Funds holding: 110 → 134 (+24)
4.15% more ownership
Funds ownership: 112.79% → 116.94% (+4.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCMC
Matrix Capital Management Company
Portsmouth,
New Hampshire
|
+$114M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$87.6M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$39.9M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$26.3M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$19.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$34.8M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$25.7M |
| 3 |
TCM
Tybourne Capital Management
Hong Kong
|
-$16.1M |
| 4 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$14.7M |
| 5 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$14.3M |
ZNTL Hedge Fund Activity: Q2 2023 in Review
134 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Zentalis Pharmaceuticals (ZNTL) for Q2 2023, worth a combined $2.32B — up 102% from $1.15B a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new ZNTL positions and 10 closed out — a net gain of 24 holders — while 59 added to existing stakes and 27 trimmed.
The largest buyer was Matrix Capital Management Company, adding an estimated $114M. The largest seller was Wellington Management Group, cutting an estimated $34.8M.
- 134 institutional investors held Zentalis Pharmaceuticals (ZNTL) as of Q2 2023, up from 110 in Q1 2023.
- Funds reported $2.32B of Zentalis Pharmaceuticals stock for Q2 2023, up 102% quarter-over-quarter.
- 34 funds opened new Zentalis Pharmaceuticals positions in Q2 2023 and 10 closed out, a net change of +24 holders.
- The largest Zentalis Pharmaceuticals buyer in Q2 2023 was Matrix Capital Management Company, an estimated $114M added.
- The largest Zentalis Pharmaceuticals seller in Q2 2023 was Wellington Management Group, an estimated $34.8M sold.
Based on aggregated 13F filings for Q2 2023.